scholarly journals Lung Cancer Treatment: Incidence and Survival: SEER Database

2019 ◽  
Vol 2 (2) ◽  
pp. 36-40
Author(s):  
Rasmy Ayman ◽  
◽  
Ameen Amal ◽  
AbdMonem Amira ◽  
◽  
...  

Lung cancer is the most common cause of cancer death worldwide, with an estimated 1.6 million deaths each year. Nearly 85% of cases have a different histological groups jointly recognized as “Non-Small Cell Lung Cancer of which lung adenocarcinoma and lung squamous cell carcinoma are the most common subtypes”.

2020 ◽  
Vol 19 (17) ◽  
pp. 2060-2071
Author(s):  
Lei Zhang ◽  
Yifang Huang ◽  
Xuedong Gan ◽  
Siying He ◽  
Xiaohuan Cheng ◽  
...  

Background: Atorvastatin belongs to the group of statins and is the leading drug for hypercholesterolemia treatment. Although, its anticancer effects are highly appreciated, its properties are still unclear. The aim of this study was to explore the underlying anticancer mechanisms induced by atorvastatin and enlarge the potential target in non-small cell lung cancer. Methods: arget genes of atorvastatin were collected by the DrugBank database. Prediction of interaction between primary targets and secondary targets was performed, and protein-protein interaction network was constructed though the STRING. Then, KEGG pathway enrichment analysis was performed with WebGestalt and ClueGO, including the pathways in non-small cell lung cancer. Furthermore, a genomic alteration analysis of the selected seed genes of atorvastatin benefit and non-small cell lung cancer pathway was conducted by cBioPortal. Finally, a survival analysis with the selected seed genes in lung cancer (lung adenocarcinoma, lung squamous cell carcinoma) was conducted using Kaplan-Meier (KM) plotter. Results: To identify seed genes, 65 potential candidate genes were screened as targets for atorvastatin using STRING with DrugBank database, while the KEGG pathway was enriched to get the overlap match of pathways in non-small cell lung cancer. Then 4 seed genes, Epidermal Growth Factor Receptor (EGFR), erb-b2 receptor tyrosine kinase 2 (ERBB2), AKT serine/threonine kinase 1 (AKT1) and tumor protein p53 (TP53), were selected and their genomic alternation were evaluated by cBioPortal. Survival analysis found that TP53 and EGFR showed a significant correlation (log rank P = 3e-07 and 0.023) with lung adenocarcinoma and lung squamous cell carcinoma, according to the KM analysis. Conclusion: Gene-phenotype connectivity for atorvastatin in non-small cell lung cancer was identified using functional/activity network analysis method, and our findings demonstrated that TP53 and EGFR could be the potential targets in cancer patients with atorvastatin therapy.


2021 ◽  
Author(s):  
Jun Zhu ◽  
Lingfei Lu ◽  
Yong Fan ◽  
Caicun Zhou

The morbidity and mortality of lung cancer, especially squamous cell carcinoma non-small cell lung cancer (NSCLC), is significantly higher than other malignant tumors. Currently, there is a lack of real-time...


2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Zhenyu Yang ◽  
Yinfang Shen ◽  
Junhong Jiang ◽  
Ziyi Liu ◽  
Chuanyong Mu

Accumulating evidence shows that histologic transformation is involved in the drug resistance of lung cancer. Moreover, it is common for lung adenocarcinoma to transform into small-cell lung cancer or squamous cell carcinoma; however, clinical cases with sarcomatoid transformation have been rarely reported. Thus, both the diagnosis and treatment of lung adenocarcinoma with sarcomatoid transformation remain difficult. Here, we discuss two patients with lung adenocarcinoma with sarcomatoid transformation—analyzing the diagnosis, clinical features, immunohistochemical characteristics, therapy, and prognosis—with the hope that this report will be used as a reference for future treatment of these patients.


2021 ◽  
Author(s):  
Jiahao Cai ◽  
Jie Gu ◽  
Di Ge ◽  
Fengkai Xu

Abstract BACKGROUNDThe incidence of lung cancer ranks first among malignant tumors all over the world. Based on the histological features, lung cancer could be divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), of which non-small cell lung cancer accounts for about 80%. NSCLC mainly includes lung squamous cell carcinoma (LUSC), lung adenocarcinoma (LUAD), and large cell lung cancer (LLC). Most of the patients were diagnosed at a late stage, which means the 5-year overall survival rate for patients was shallow. According to the situation, new biomarkers are needed to recognize patients at high risk, which would help give them appropriate treatment to improve their outcomes.Ferroptosis, an important iron-dependent cell death driven by oxidative phospholipid damage and characterized by lipid peroxidation, was recently found to play a novel role in several cancers. Existing research have identified many genes related to ferroptosis in tumor tissues. However, research on ferroptosis-genes-related long non-coding RNA (lncRNA) in lung cancer is still insufficient. METHODSWe acquired the statistics from the public database TCGA Lung Squamous Cell Carcinoma (LUSC). Then a multi-lncRNA signature was constructed to recognize patients at high risk based on differentially expressed ferroptosis-genes-related lncRNAs in lung squamous cell carcinoma. RESULTSWe finally identified eight differently expressed ferroptosis-genes-related lncRNAs are predictive of outcomes in LUSC patients. Kaplan-Meier analyses revealed that the high-risk-related lncRNAs signature has strong predictive power for poor LUSC prognosis (AUC=0.686). Our risk-predictive model was superordinate to the traditional predictive method based on clinicopathological characteristics (Stage, AUC=0.563). Gene set enrichment analysis (GSEA) revealed signaling pathways that ferroptosis-genes-related lncRNAs may participate in. Further study of immune function-related gene sets showed that parainflammation, APC co-stimulation, inflammation-promoting, T cell co-stimulation, Type I and type II INF response were significantly associated with risk-related lncRNAs signature. Immune checkpoint-related genes such as PDCD-1, CD70, CD28, and CD27, etc., also expressed differently between the two risk groups.CONCLUSIONThe specific differentially expressed ferroptosis-related lncRNAs have a strong predictive effect on the prognosis in patients with lung squamous cell carcinoma.


Sign in / Sign up

Export Citation Format

Share Document